Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide plus R-CHOP versus placebo plus R-CHOP in previously untreated high-risk large B-cell lymphoma
NL-OMON59894Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and 1 more comparing Golcadomide + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON59894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59894.